Neurofibroma differential diagnosis

	Neurofibroma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neurofibroma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neurofibroma differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neurofibroma differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neurofibroma differential diagnosis
CDC on Neurofibroma differential diagnosis
Neurofibroma differential diagnosis in the news
Blogs on Neurofibroma differential diagnosis
Directions to Hospitals Treating Neurofibroma
Risk calculators and risk factors for Neurofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Neurofibroma must be differentiated from:^[1]

Schwannoma
Dermatofibrosarcoma protuberans (DFSP)
Ganglioneuroma
Melanocytic nevus
Myxoid liposarcoma
Myxoma
Plexiform schwannoma
Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background
Malignant peripheral nerve sheath tumor: has marked atypia and increased mitotic activity, may have necrosis